Gossas T, Vrang L, Henderson I, Sedig S, Sahlberg C, Lindström E, Danielson UH, N-S Arch Pharamacol, 2012, 385:219-224.

Read the rest of this page »

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.

Read the rest of this page »

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University in 2006, was recognised as the fastest growing young biotech in Sweden by management consultants Deloitte at the “Technology Rising Stars” prize giving ceremony in Stockholm this week.

Read the rest of this page »

Beactica presents at Select Bioscience’s Discovery Chemistry Congress in Munich, Germany.

Beactica CSO presents at 2011 Nordic Biacore and MicroCal users’ meeting in Copenhagen, Denmark.

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as “Technology Rising Stars” by management consultants Deloitte.

Read the rest of this page »

Beactica participates in Protein Structure Determination in Industry 2011 (PSDI) in Stenungsbaden, Sweden.

Beactica participates in BIO-Europe 2011 in Duesseldorf, Germany.

Beactica presents at Developments in Protein Interaction Analysis (DiPIA) in Boston, MA.

Beactica participates in the 12th Annual Drug Discovery Leaders Summit in Zurich, Switzerland.

Christopeit T, Stenberg G, Gossas T, Nyström S, Baraznenok V, Lindström E, Danielson UH. Anal Biochem, 2011, 414:14-22.

Read the rest of this page »

Beactica presents at CHI’s 9th Annual Next-Gen Kinase Inhibitors in Cambridge, MA.

Beactica CSO holds webinar hosted by Biacore Life Sciences, GE Healthcare. Register free by clicking here.

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.

Read the rest of this page »

Elinder M, Geitmann M, Gossas T, Källblad P, Winquist J, Nordström H, Hämäläinen M, Danielson UH. J Biomol Screen, 2011, 16:15-25.

Read the rest of this page »

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza.

Read the rest of this page »

Beactica presents at CHI’s 6th Annual Drug Discovery Chemistry conference in San Diego, CA.

Beactica, the leading Swedish fragment-based drug discovery company, today announced the publication of two key papers based on in-house research in the field-leading Journal of Medicinal Chemistry*. The papers present methodological advances in SPR biosensor-based drug discovery targeting structurally dynamic proteins, a significant challenge for the pharmaceutical industry, that have been implemented in Beactica’s Sprint™ platform.

Read the rest of this page »

Geitmann M, Elinder M, Seeger C, Brandt P, de Esch IJ, Danielson UH. J Med Chem, 2011, 54:699-708.

Read the rest of this page »

Brandt P, Geitmann M, Danielson UH. J Med Chem, 2011, 54:709-18.

Read the rest of this page »

Gustafsson SS, Vrang L, Terelius Y, Danielson UH. Analytical Biochemistry, 2011, 409:163-75.

Read the rest of this page »

Beactica, the leading Swedish fragment-based drug discovery company, today announced that board member Gisela Sitbon will assume the position of Chairman and that Mr Jan Mellberg will join its Board, both effective immediately.

Read the rest of this page »

Beactica Principal Scientist presents at the 10th Annual Target & Tools: Protein Kinases Conference in Berlin, Germany.

Beactica, the Swedish fragment-based drug discovery company, today announced an important move to address the need for increased data quality and higher capacity in understanding molecular interactions. Growing customer demand for solutions to ever more complex research challenges has led Beactica to invest in the world’s most sophisticated SPR biosensor to date, the Biacore 4000. The instrument will enable Beactica to offer more advanced experimental designs and a deeper interpretation of interaction analysis data so that stronger therapeutic candidates can be developed.

Read the rest of this page »

Beactica, the Swedish fragment-based drug discovery company, today announced the publication of three key papers in leading scientific journals*. The papers describe important work towards the discovery of novel drugs targeting Cys-loop ion channel receptors, a significant family of drug targets involved in various neurological diseases, for example epilepsy.

Read the rest of this page »

de Kloe GE, Retra K, Geitmann M, Källblad P, Nahar T, van Elk R, Smit AB, van Muijlwijk-Koezen JE, Leurs R, Irth H, Danielson UH, de Esch IJ. J Med Chem, 2010, 53:7192–7201.

Read the rest of this page »

Geitmann M, Retra K, de Kloe GE, Homan E, Smit AB, de Esch IJ, Danielson UH. Biochemistry. 2010, 49:8143-54.

Read the rest of this page »

Beactica participates in BIO-Europe Partnering 2010 in Munich, Germany.

Beactica participates in Fragment-Based Lead Generation 2010 in Philadelphia, PA.

Beactica’s Chief Scientific Officer presents at XXth National Meeting on Medicinal Chemistry in Padova, Italy.

Beactica’s Chief Executive Officer speaks at The 11th Annual Drug Discovery Leaders Summit in Montreaux, Switzerland.

Beactica Senior Scientist presents at The 5th Annual Protein Kinases in Drug Discovery Conference in Boston, USA.

Beactica Senior Scientist presents at Drug Discovery Chemistry 2010 in San Diego, USA.

Beactica’s Chief Scientific Officer presents at The International Workshop on New Approaches in Drug Design & Discovery in Schloss Rauischholzhausen, Germany.

Beactica Senior Scientist presents at The 5th Annual Protein Kinases in Drug Discovery Conference in Boston, USA.

Beactica participates in BIO-Europe Partnering 2009 in Vienna, Austria.

Beactica presents a poster at Fragment-Based Lead Discovery 2009 in York, UK.

Beactica’s Chief Scientific Officer presents at the Gordon Research Conference on Computer-Aided Drug Design in Tilton, USA.

Beactica’s Chief Scientific Officer presents at Fragment-Based Lead Discovery Summit in London, UK.

Beactica’s Chief Executive Officer presents at 10th Annual Drug Discovery Leaders Summit in Montreaux, Switzerland.

Beactica’s Chief Scientific Officer presents at Trends in Drug Research, the 27th Noordwijkerhout-Camerino-Cyprus Conference in Noordwijkerhout, The Netherlands.

Beactica’s Chief Executive Officer presents at Drug Discovery Chemistry 2009 in San Diego, USA.

Domínguez JL, Christopeit T, Villaverde MC, Gossas T, Otero JM, Nyström S, Baraznenok V, Lindström E, Danielson UH, Sussman F. Biochemistry. 2010, 49:7255-63.

Read the rest of this page »

Beactica participates in Fragments 2009 in Alderley Park, UK.

Beactica Senior Scientist presents at BIOPROSP 2009 in Tromsoe, Norway.

Beactica’s Chief Scientific Officer is part of expert commentary panel on the Nobel Committee’s press conference in conjunction with the announcement of the 2008 Nobel Prize in Chemistry.

Beactica’s Chief Executive Officer presents at Drug Discovery 2008 in Bournemouth, UK.

Beactica participates in Business Forum Partnering at BIO 2008 in San Diego, USA.

Beactica participates in Label Free Technologies in Drug Discovery in Dresden, Germany.

Beactica’s Chief Executive Officer presents at Drug Discovery Chemistry 2008 – Tools, Targets & Therapies in La Jolla, USA.